These criteria define progression as the development of new metastatic lesions or an increase in PSMA PET tumor volume.24,25 Similar to our findings, a recent study investigated metastatic bone lesions in 388 patients who underwent a vertex-to-toe total body PSMA PET/CT for PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.